Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 46.25 GBp
Change Today +0.50 / 1.09%
Volume 163.9K
As of 4:46 AM 08/5/15 All times are local (Market data is delayed by at least 15 minutes).

sinclair is pharma plc (SPH) Snapshot

46.00 GBp
Previous Close
45.75 GBp
Day High
47.25 GBp
Day Low
46.00 GBp
52 Week High
07/23/15 - 48.00 GBp
52 Week Low
10/10/14 - 23.50 GBp
Market Cap
Average Volume 10 Days
-0.02 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for SINCLAIR IS PHARMA PLC (SPH)

Related News

No related news articles were found.

sinclair is pharma plc (SPH) Related Businessweek News

No Related Businessweek News Found

sinclair is pharma plc (SPH) Details

Sinclair IS Pharma plc, a specialty pharmaceutical company, provides surface technology and delivery systems for aesthetics, wound care, and skin care treatments worldwide. The company’s aesthetic dermatology solutions include Kelo-cote, a topical silicone gel used for the management and prevention of hypertrophic and keloid scars; Kelo-Stretch, which helps in rebuilding damaged collagen and regaining skin elasticity; Sculptra, a volumizer designed to stimulate natural collagen growth; Perfectha for the treatment of wrinkles and facial contours; Ellansé, which offers four dermal filler options for facial aesthetic treatments; and Silhouette Soft, a skin tightening and own collagen stimulator. Its wound care products comprise Flammazine and Flammacerium that are used in the prevention and treatment of severe burns and wounds; and Aloclair Plus for relieving the pain caused by aphthous mouth ulcers and other minor oral lesions. The company’s skin care products include Atopiclair, a non-steroidal topical treatment for the symptomatic relief of atopic, contact allergic, and irritant dermatitis; Papulex, a dermocosmetic product used for cleansing, hydrating, and protecting acne prone skin; Sebclair for the management of skin and scalp seborrhoeic dermatitis; and Bio-Taches products for preventing and reducing pigmentation disorders, such as chloasma, melasma, or dyschromia. Further, it offers other products consisting of Variquel/Haemopressin for the treatment of bleeding oesophageal varices; Aloxi, a 2nd generation 5HT3 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting associated with highly emetogenic chemotherapy and moderately emetogenic chemotherapy; and Decapinol for plaque management. Sinclair IS Pharma plc offers its solutions to hospitals, plastic surgeons, dermatologists, and pharmacists. The company was founded in 1971 and is headquartered in London, the United Kingdom.

161 Employees
Last Reported Date: 10/31/14
Founded in 1971

sinclair is pharma plc (SPH) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: 630.0K GBP
Chief Operating Officer and Director
Total Annual Compensation: 392.0K GBP
Compensation as of Fiscal Year 2014.

sinclair is pharma plc (SPH) Key Developments

Sinclair IS Pharma plc Receives US FDA Approval for Silhouette Instalift

Sinclair IS Pharma plc announced that it has received US FDA approval for Silhouette Instalift. Silhouette Instalift, Sinclair's patented, reabsorbable, PLGA suture with bi-directional cones was filed with the FDA in July 2014. The FDA has accepted the Group's application with an approved label stating The Silhouette Instalift device is indicated for use in mid-face suspension surgery to fixate the cheek sub dermis in an elevated position. FDA approval means Sinclair is now free to sell Silhouette Instalift in the US market with immediate effect. Based on independent market research management expect that annual peak sales for Silhouette Instalift in the US will be in excess of $200 million five years post launch, equivalent to approximately 300,000 patient treatments per year. The distribution model for Silhouette Instalift in the US is currently being evaluated as part of the strategic review process announced on 25 November 2014.

Sinclair IS Pharma plc, H1 2015 Earnings Call, Feb 17, 2015

Sinclair IS Pharma plc, H1 2015 Earnings Call, Feb 17, 2015

Sinclair IS Pharma plc Announces Unaudited Consolidated Earnings Results for the Six Months Ended December 31, 2014; Provides Earnings Guidance for the First Half and Second Half of Fiscal Year 2015

Sinclair IS Pharma plc announced unaudited consolidated earnings results for the six months ended December 31, 2014. For the period, the company’s revenues were £32.0 million compared to £24.5 million for the same period last year representing reported growth of 31% and 37% on a constant currency basis. In line with board expectations, net debt increased to £44.2 million at 31 December 2014 from £40.2 million at 30 June 2014. For the year, the company reported operating loss of £2,940,000 against £2,322,000 a year ago. Loss before taxation was £10,797,000 against £2,499,000 a year ago. Loss for the year from continuing operations was £10,675,000 or 2.1 pence basic and diluted per share against £2,356,000 or 0.8 pence basic and diluted per share a year ago. Loss for the year was £10,675,000 or 2.1 pence basic and diluted per share against £3,400,000 or 0.8 pence basic and diluted per share a year ago. Adjusted basic and diluted earnings per share were 0.5 pence against 0.1 pence a year ago. Net cash used in operating activities was £4,232,000 against £3,359,000 a year ago. Purchases of property, plant and equipment were £306,000 against £10,000 a year ago. Purchase of intangible assets was £583,000 against £176,000 a year ago. Adjusted EBITDA from continuing operations was £3,329,000 against £1,062,000 a year ago. The company provided earnings guidance for the first half and second half of fiscal year 2015. For the first half of fiscal year 2015, the company reports that revenue, in-market uptake and operational trends in the group's aesthetic portfolio remain strong and are very encouraging. Training courses are fully booked and physician interest in the group's aesthetics portfolio at industry congresses continues to be very high. In addition to the current trends, multiple product and geographical opportunities point to sustainable strong growth despite a weaker Euro. Non aesthetics growth was above trend but is expected to return to a stable low-growth trend and beyond. Both gross and EBITDA margin improvement is expected to be strong for second half of fiscal year 2015 and beyond. Gross margin is likely to improve sharply in the short term as aesthetics manufacturing costs decline combined with a trend of improving sales mix. The Board therefore expects a strong performance although factors including the weak Euro and ongoing difficulties encountered in Russia with Silhouette will have an impact on the outcome as whole.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SPH:LN 46.25 GBp +0.50

SPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SPH.
View Industry Companies

Industry Analysis


Industry Average

Valuation SPH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.2x
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SINCLAIR IS PHARMA PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at